- Home
- LSH vs AYTU Comparison
LSH vs AYTU Comparison
Compare LSH & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSH
- AYTU
- Stock Information
- Founded
- LSH 2018
- AYTU N/A
- Country
- LSH United States
- AYTU United States
- Employees
- LSH N/A
- AYTU N/A
- Industry
- LSH
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- LSH
- AYTU Health Care
- Exchange
- LSH NYSE
- AYTU Nasdaq
- Market Cap
- LSH 7.3M
- AYTU 8.3M
- IPO Year
- LSH 2024
- AYTU N/A
- Fundamental
- Price
- LSH $1.00
- AYTU $1.05
- Analyst Decision
- LSH
- AYTU
- Analyst Count
- LSH 0
- AYTU 0
- Target Price
- LSH N/A
- AYTU N/A
- AVG Volume (30 Days)
- LSH 36.9K
- AYTU 31.3K
- Earning Date
- LSH 05-01-2025
- AYTU 05-14-2025
- Dividend Yield
- LSH N/A
- AYTU N/A
- EPS Growth
- LSH N/A
- AYTU N/A
- EPS
- LSH N/A
- AYTU N/A
- Revenue
- LSH $16,927,719.00
- AYTU $77,232,000.00
- Revenue This Year
- LSH N/A
- AYTU N/A
- Revenue Next Year
- LSH N/A
- AYTU $8.14
- P/E Ratio
- LSH N/A
- AYTU N/A
- Revenue Growth
- LSH 2.84
- AYTU N/A
- 52 Week Low
- LSH $0.88
- AYTU $0.95
- 52 Week High
- LSH $5.37
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- LSH N/A
- AYTU 41.21
- Support Level
- LSH N/A
- AYTU $0.99
- Resistance Level
- LSH N/A
- AYTU $1.10
- Average True Range (ATR)
- LSH 0.00
- AYTU 0.08
- MACD
- LSH 0.00
- AYTU 0.01
- Stochastic Oscillator
- LSH 0.00
- AYTU 55.56
About LSH LAKESIDE HOLDING LTD
Lakeside Holding Ltd i an integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including cross-border freight consolidation and forwarding services; customs clearance services; warehousing and distribution services and U.S. domestic ground transportation services.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.